← 홈

Catalyst · Landscape

향후 6개월 내 primary completion 예정인 활성 임상과 큐레이션·승인 프로그램의 phase 분포입니다. CT.gov completion date 기반 추정이며 공식 readout 일정과 다를 수 있습니다. RSS

파이프라인 Phase 분포

큐레이션·FDA·임상 3건 이상 프로그램 2029개 — catalyst 일정과 별도의 전체 파이프라인 스냅샷입니다.

Preclinical
132
Phase 1
491
Phase 2
979
Phase 3
293
Approved
134

Catalyst target · modality

향후 6개월 catalyst 4건 · 타깃·모달리티 분포

Antibody 4
Extranodal
2
CD20
1
B-cell
1

향후 6개월 Catalyst(4 / 80)

활성 recruiting/enrolling 임상 · CT.gov completion 기준 · 상위 80건 표시

완료 예정프로그램PhaseStatusEndpoint신뢰도NCT
2026년 9월AvastinAntibody · Extranodal NK/T-cell Lymphoma, Nasal TypPhase 3Active, not recruitingDisease-Free Survival (DFS) as Assessed Radiographically by Investigator or by Histopathologic Confirmation of Suspected Disease Recurrence; Overall Survival (OS)신뢰 높음NCT04634877
2026년 9월AvastinAntibody · Extranodal NK/T-cell Lymphoma, Nasal TypPhase 1, Phase 2Active, not recruitingInitial Stage Cohorts: Disease Control Rate (DCR) at Week 12; Second Stage Cohort: Objective Response Rate (ORR); Second Stage Cohorts: DCR at Week 24신뢰 높음NCT02734004
2026년 9월Columvi (glofitamab)Antibody · CD20 × CD3Phase 2Active, not recruitingEnd of Treatment Complete Response (EOT CR) Rate보통NCT04980222
2026년 9월ObinutuzumabAntibody · B-cell LymphomaN/ARecruitingProgression-free survival rate at 24 months신뢰 높음NCT05950997
  • 2026년 9월신뢰 높음
    Avastin

    Antibody · Extranodal NK/T-cell Lymphoma, Nasal Typ · Phase 3

    Disease-Free Survival (DFS) as Assessed Radiographically by Investigator or by Histopathologic Confirmation of Suspected Disease Recurrence; Overall Survival (OS)

    NCT04634877
  • 2026년 9월신뢰 높음
    Avastin

    Antibody · Extranodal NK/T-cell Lymphoma, Nasal Typ · Phase 1, Phase 2

    Initial Stage Cohorts: Disease Control Rate (DCR) at Week 12; Second Stage Cohort: Objective Response Rate (ORR); Second Stage Cohorts: DCR at Week 24

    NCT02734004
  • 2026년 9월보통
    Columvi (glofitamab)

    Antibody · CD20 × CD3 · Phase 2

    End of Treatment Complete Response (EOT CR) Rate

    NCT04980222
  • 2026년 9월신뢰 높음
    Obinutuzumab

    Antibody · B-cell Lymphoma · N/A

    Progression-free survival rate at 24 months

    NCT05950997